Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study

European Journal of Cancer

Volumn 49, Issue 15, 2013, Pages 3122-3130

  Benson III, Al B ^a   Geschwind, Jean Francois ^b   Mulcahy, Mary F ^a   Rilling, William ^c   Siskin, Gary ^d   Wiseman, Greg ^e   Cunningham, James ^f   Houghton, Bonny ^f   Ross, Mason ^f   Memon, Khairuddin ^a   Andrews, James ^e   Fleming, Chad J ^e   Herman, Joseph ^b   Nimeiri, Halla ^a   Lewandowski, Robert J ^a   Salem, Riad ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d ALBANY MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f MDS Inc   (Canada)

Author keywords

Chemotherapy; Liver metastases; Progressive disease; Radioembolisation; TheraSphere; Yttrium 90

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BEVACIZUMAB; BILIRUBIN; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; MICROSPHERE; OCTREOTIDE; OXALIPLATIN; PANITUMUMAB; YTTRIUM 90;

ACIDOSIS; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASCITES; CHEMOEMBOLIZATION; COLORECTAL CANCER; DEHYDRATION; DISEASE CONTROL; DISEASE COURSE; DOSIMETRY; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL OBSTRUCTION; GOOD CLINICAL PRACTICE; HEALTH CARE QUALITY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPONATREMIA; INFECTION; INVESTIGATIONAL DEVICE EXEMPTION; LIVER DYSFUNCTION; LIVER METASTASIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; OBSTRUCTION; OVERALL SURVIVAL; PAIN; PATIENT CARE; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIOEMBOLIZATION; REPRODUCIBILITY; THROMBOSIS; TUMOR LYSIS SYNDROME; VOMITING;

CHEMOTHERAPY; LIVER METASTASES; PROGRESSIVE DISEASE; RADIOEMBOLISATION; THERASPHERE; YTTRIUM-90;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; YTTRIUM RADIOISOTOPES;

EID: 84884907521     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.05.012     Document Type: Article

References (54)

1. J.A. Norton Surgical treatment of neuroendocrine metastases Best Pract Res Clin Gastroenterol 19 4 2005 577 583
2. J.S. Tomlinson, W.R. Jarnagin, and R.P. DeMatteo Actual 10-year survival after resection of colorectal liver metastases defines cure J Clin Oncol 25 29 2007 4575 4580
3. A.R. Sasson, and E.R. Sigurdson Surgical treatment of liver metastases Semin Oncol 29 2 2002 107 118
4. M.P. Lutz, H. Wilke, and D.J. Wagener Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie J Clin Oncol 25 18 2007 2580 2585
5. M. Albert, M.V. Kiefer, and W. Sun Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol Cancer 117 2 2011 343 352
6. X.D. Dong, and B.I. Carr Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients Med Oncol 28 1-suppl. 2011 286 290
7. R. Martin, J. Joshi, and K. Robbins Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study Ann Surg Oncol 18 1 2011 192 198
8. S. Siena, M. Peeters, and E. Van Cutsem Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab Br J Cancer 97 11 2007 1469 1474
9. E. Berber, N. Flesher, and A.E. Siperstein Laparoscopic radiofrequency ablation of neuroendocrine liver metastases World J Surg 26 8 2002 985 990
10. R. Lencioni, L. Crocetti, D. Cioni, C. Della Pina, and C. Bartolozzi Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises Invest Radiol 39 11 2004 689 697
11. E. Van Cutsem Integration of the anti-EGFR agent panitumumab into clinical practice in metastatic colorectal cancer Clin Adv Hematol Oncol 5 8 2007 611 613
12. R. Salem, and K.G. Thurston Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 1: technical and methodologic considerations J Vasc Interv Radiol 17 8 2006 1251 1278
13. R. Salem, and K.G. Thurston Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 2: special topics J Vasc Interv Radiol 17 9 2006 1425 1439
14. R. Salem, and K.G. Thurston Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction J Vasc Interv Radiol 17 10 2006 1571 1593
15. C. Breedis, and G. Young The blood supply of neoplasms in the liver Am J Pathol 30 5 1954 969 977
16. R. Salem, R.J. Lewandowski, and M.F. Mulcahy Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 1 2010 52 64
17. R. Salem, R.J. Lewandowski, and B. Atassi Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival J Vasc Interv Radiol 16 12 2005 1627 1639
18. B. Sangro, L. Carpanese, and R. Cianni Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation Hepatology 54 3 2011 868 878
19. P. Hilgard, M. Hamami, and A.E. Fouly Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival Hepatology 52 5 2010 1741 1749
20. M.F. Mulcahy, R.J. Lewandowski, and S.M. Ibrahim Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres Cancer 115 9 2009 1849 1858
21. K. Memon, R.J. Lewandowski, and M.F. Mulcahy Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes Int J Radiat Oncol Biol Phys 83 3 2012 887 894
22. A.S. Kennedy, D. Coldwell, and C. Nutting Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience Int J Radiat Oncol Biol Phys 65 2 2006 412 425
23. A. Hendlisz, M. Van den Eynde, and M. Peeters Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy J Clin Oncol 28 23 2010 3687 3694
24. A.S. Kennedy, W.A. Dezarn, and P. McNeillie Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients Am J Clin Oncol 31 3 2008 271 279
25. R. Salem, K.G. Thurston, B.I. Carr, J.E. Goin, and J.F. Geschwind Yttrium-90 microspheres: radiation therapy for unresectable liver cancer J Vasc Interv Radiol 13 9 Pt 2 2002 S223 S229
26. D.M. Liu, R. Salem, and J.T. Bui Angiographic considerations in patients undergoing liver-directed therapy J Vasc Interv Radiol 16 7 2005 911 935
27. R.J. Lewandowski, K.T. Sato, and B. Atassi Radioembolization with (90)y microspheres: angiographic and technical considerations Cardiovasc Intervent radiol 30 4 2007 571 592
28. R. Salem, R.J. Lewandowski, and K.T. Sato Technical aspects of radioembolization with 90Y microspheres Tech Vasc Interv Radiol 10 1 2007 12 29
29. R. Salem, R.J. Lewandowski, and V.L. Gates Research reporting standards for radioembolization of hepatic malignancies J Vasc Interv Radiol 22 3 2011 265 278
30. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
31. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
32. D.R. Cox, and D. Oaks Analysis of survival data 1984 Chapman & Hall London
33. R. Salem, R.J. Lewandowski, and L. Kulik Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology 140 2 2011 497 e2 507 e2
34. K.T. Sato, R.J. Lewandowski, and M.F. Mulcahy Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres - safety, efficacy, and survival Radiology 247 2 2008 507 515
35. R. Murthy, C. Eng, and S. Krishnan Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab J Vasc Interv Radiol 18 12 2007 1588 1591
36. A. Forner, C. Ayuso, and M. Varela Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation in solid tumors reliable? Cancer 115 3 2009 616 623
37. B. Atassi, A.K. Bangash, and A. Bahrani Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay Radiographics 28 1 2008 81 99
38. E. Van Cutsem, M. Peeters, and S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 13 2007 1658 1664
39. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 20 2007 2040 2048
40. A. Grothey, A.F. Sobrero, and S. Siena Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies ASCO Meeting Abstr 30 4-suppl. 2012 LBA385
41. C. Loewe, M. Schindl, and M. Cejna Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results AJR Am J Roentgenol 180 5 2003 1379 1384
42. B.K. Eriksson, E.G. Larsson, and B.M. Skogseid Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors Cancer 83 11 1998 2293 2301
43. T. de Baere, F. Deschamps, and C. Teriitheau Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results J Vasc Interv Radiol 19 6 2008 855 861
44. T.J. Vogl, T. Gruber, N.N. Naguib, R. Hammerstingl, and N.E. Nour-Eldin Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols AJR Am J Roentgenol 193 4 2009 941 947
45. E. Raymond, L. Dahan, and J.L. Raoul Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 6 2011 501 513
46. J.C. Yao, M.H. Shah, and T. Ito Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 6 2011 514 523
47. C. Chirila, D. Odom, and G. Devercelli Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer Int J Colorectal Dis 27 5 2012 623 634
48. K.R. Johnson, C. Ringland, and B.J. Stokes Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis Lancet Oncol 7 9 2006 741 746
49. D.J. Sargent, S. Patiyil, and G. Yothers End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group J Clin Oncol 25 29 2007 4569 4574
50. D.J. Sargent, H.S. Wieand, and D.G. Haller Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials J Clin Oncol 23 34 2005 8664 8670
51. G. Ercolani, G.L. Grazi, and M. Ravaioli The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases Ann Surg Oncol 12 6 2005 459 466
52. L.E. Harrison, M.F. Brennan, and E. Newman Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients Surgery 121 6 1997 625 632
53. S.I. Schwartz Hepatic resection for noncolorectal nonneuroendocrine metastases World J Surg 19 1 1995 72 75
54. J. Weitz, L.H. Blumgart, and Y. Fong Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma Ann Surg 241 2 2005 269 276